Clinical Trials
9 trialsNCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT02364713 2025-12-11
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
Phase 2 Terminated
NCT04336943 2025-08-11
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
University of Washington
Phase 2 Terminated
NCT04370834 2025-02-04
Tocilizumab for Patients With Cancer and COVID-19 Disease
National Cancer Institute (NCI)
Phase 2 Terminated
NCT03439085 2024-07-09
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02923739 2024-03-13
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04372927 2023-06-13
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
University of Washington
Phase 2 Terminated
NCT03776864 2023-05-03
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
University of Washington
Phase 2 Terminated
NCT02452463 2020-04-06
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
Roswell Park Cancer Institute
Phase 2 Terminated